Evidence map›Paper›PMID 40817397›Full record

Trial reportScientific reports2025

The impacts of Crocin on serum cytokines concentrations in participants with metabolic syndrome: a double-blind randomized clinical trial study.

Razie Rezaiee, Hamideh Ghazizadeh, Susan Darroudi, Roshanak Ghaffarian Zirak, Mohadese Rohban, Marziyeh Eidi, Irandokht Nikbakht Jam, Ali Asghar Mahmoudi, Farzin Hadizadeh, Malihe Aghasizadeh and 2 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Razie RezaieeMetabolic Syndrome Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Hamideh GhazizadehMetabolic Syndrome Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Susan DarroudiMetabolic Syndrome Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Roshanak Ghaffarian ZirakMetabolic Syndrome Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Mohadese RohbanMetabolic Syndrome Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Marziyeh EidiMetabolic Syndrome Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Irandokht Nikbakht JamMetabolic Syndrome Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Ali Asghar MahmoudiMetabolic Syndrome Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Farzin HadizadehBiotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Malihe AghasizadehStudent Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Abbas MohtashamianStudent Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Majid Ghayour-MobarhanMetabolic Syndrome Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. ghayourm@mums.ac.ir.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to investigate the effect of Crocin on the inflammatory cytokines profile in patients with Metabolic syndrome (Mets). Twenty-eight patients with Mets (15 cases and 13 controls) were randomly selected by the International Diabetes Federation (IDF) definite criteria in a double-blind randomized clinical trial. Participants were divided into two treatment groups, a group received 15 mg of Crocin (two tablets per day), and the other one received a placebo for eight weeks. Inflammatory and growth factors were measured using a sandwich chemiluminescence assay, before and after treatment. Our results indicated that inflammatory factors including IL-2, IL-10, VEGF and INF γ, were significantly reduced (P < 0.05) in patients with Mets after Crocin treatment. Moreover, no significant difference was detected among the other biochemical factors (lipid profile and FBG) between two groups. The results showed the exclusive impact of Crocin on the reduction of serum inflammatory cytokines. Crocin has the potential to be further investigated as a useful therapeutic factor in inflammatory diseases.Clinical trial registration number: IRCT2013080514279N1, Registration date: 01/02/2015.

Indexed as

CarotenoidsCytokinesMetabolic SyndromeAdultDouble-Blind MethodFemaleHumansMaleMiddle AgedCarotenoidscrocinCytokinesCytokines concentrationMetabolic syndromeRandomized double-blind clinical trialSaffron

Identifiers

PMID40817397
PMCPMC12356862

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.